<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lee TH</submitter><funding>Ministry of Health and Welfare</funding><pagination>247-259</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7746480</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(4)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>In this study, we aimed to evaluate and compare the treatment indication for patients with glucocorticoid-induced osteoporosis (GIOP) in various clinical practice guidelines.&lt;h4>Methods&lt;/h4>We searched for potentially relevant studies conducted from January 2000 to March 2020 using online databases, including PubMed, Ovid-EMBASE, Guidelines International Network, National Institute for Health and Clinical Excellence, KoreaMed, KMbase, and KoMGI. We reviewed and analyzed the guidelines that included recommendations on GIOP and fulfilled the inclusion criteria.&lt;h4>Results&lt;/h4>A total of 94 articles were selected based on review of the title and abstract; 14 guidelines were assessed upon reviewing the full text. The bone mineral density score for therapeutic intervention of GIOP in postmenopausal women was presented in 7 guidelines, among which 3 guidelines set a T-score of -2.5 or lower and the other 4 guidelines proposed a less stringent cut-off point of -1.5 or lower. Among the 10 guidelines published since 2012 after the emergence of the fracture risk assessment tool (FRAX), 6 guidelines included FRAX in their criteria for defining intervention thresholds. However, they were further divided into fixed-probability (n=3) and age-dependent (n=3) thresholds based on the country.&lt;h4>Conclusions&lt;/h4>Recently developed guidelines use FRAX as the criterion for establishing the treatment of patients with GIOP. However, these intervention thresholds need to be adapted for each country.</pubmed_abstract><journal>Journal of bone metabolism</journal><pubmed_title>Intervention Thresholds for Treatment in Patients with Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines.</pubmed_title><pmcid>PMC7746480</pmcid><funding_grant_id>HI19C0481</funding_grant_id><funding_grant_id>HC19C0047</funding_grant_id><pubmed_authors>Song YJ</pubmed_authors><pubmed_authors>Kim H</pubmed_authors><pubmed_authors>Lee TH</pubmed_authors><pubmed_authors>Sung YK</pubmed_authors><pubmed_authors>Cho SK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Intervention Thresholds for Treatment in Patients with Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines.</name><description>&lt;h4>Background&lt;/h4>In this study, we aimed to evaluate and compare the treatment indication for patients with glucocorticoid-induced osteoporosis (GIOP) in various clinical practice guidelines.&lt;h4>Methods&lt;/h4>We searched for potentially relevant studies conducted from January 2000 to March 2020 using online databases, including PubMed, Ovid-EMBASE, Guidelines International Network, National Institute for Health and Clinical Excellence, KoreaMed, KMbase, and KoMGI. We reviewed and analyzed the guidelines that included recommendations on GIOP and fulfilled the inclusion criteria.&lt;h4>Results&lt;/h4>A total of 94 articles were selected based on review of the title and abstract; 14 guidelines were assessed upon reviewing the full text. The bone mineral density score for therapeutic intervention of GIOP in postmenopausal women was presented in 7 guidelines, among which 3 guidelines set a T-score of -2.5 or lower and the other 4 guidelines proposed a less stringent cut-off point of -1.5 or lower. Among the 10 guidelines published since 2012 after the emergence of the fracture risk assessment tool (FRAX), 6 guidelines included FRAX in their criteria for defining intervention thresholds. However, they were further divided into fixed-probability (n=3) and age-dependent (n=3) thresholds based on the country.&lt;h4>Conclusions&lt;/h4>Recently developed guidelines use FRAX as the criterion for establishing the treatment of patients with GIOP. However, these intervention thresholds need to be adapted for each country.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2024-11-14T06:41:56.865Z</modification><creation>2021-02-20T17:15:40Z</creation></dates><accession>S-EPMC7746480</accession><cross_references><pubmed>33317228</pubmed><doi>10.11005/jbm.2020.27.4.247</doi></cross_references></HashMap>